Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2002199 | 0.96 | KMT2A (0.41) | KMT2ARAB9ANPC1MEN1CA12 | |
| SCHEMBL17856071 | 0.87 | KMT2A (0.44) | KMT2ARAB9ANPC1MEN1ALDH1A1 | |
| SCHEMBL28171208 | 0.87 | KMT2A (0.46) | KMT2ARAB9ANPC1MEN1ALDH1A1 | |
| SCHEMBL19900366 | 0.79 | NR1H4 (0.43) | CA12CA1CA2CA7CA9 | |
| SCHEMBL17843213 | 0.78 | TSHR (0.39) | KMT2AMEN1CA12CA1CA2 | |
| SCHEMBL17839763 | 0.78 | KMT2A (0.41) | KMT2ARAB9ANPC1MEN1ALDH1A1 | |
| SCHEMBL17843207 | 0.78 | TSHR (0.38) | KMT2AMEN1ALDH1A1TSHRPKM | |
| SCHEMBL20749500 | 0.76 | TSHR (0.37) | KMT2AMEN1ALDH1A1TSHRPKM | |
| SCHEMBL26485417 | 0.76 | GPBAR1 (0.48) | KMT2ARAB9AMEN1ALDH1A1TSHR | |
| SCHEMBL17839920 | 0.75 | KMT2A (0.39) | KMT2ARAB9ANPC1MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108064223-B | FXR (NR1H4) MODULATING COMPOUNDS CONTAINING HYDROXY GROUPS | 吉利德科学公司 | 2021-06-01 | — | — | CN | disclosed |
| CN-107108595-B | Novel FXR (NR1H4) modulating compounds | 吉利德科学公司 | 2021-04-06 | — | — | CN | disclosed |
| EP-3233850-B1 | HYDROXY CONTAINING FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2019-04-03 | — | — | EP | disclosed |
| EP-3233831-B1 | NOVEL FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-3233831-B1 | NOVEL FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-3233831-A1 | NOVEL FXR (NR1H4) MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9751874-B2 | Hydroxy containing FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20160176861-A1 | HYDROXY CONTAINING FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2016-06-23 | — | — | US | disclosed |
| WO-2016096116-A1 | NOVEL FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016096115-A1 | HYDROXY CONTAINING FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016096116-A1 | NOVEL FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176861-A1 | HYDROXY CONTAINING FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H3, NR1H2 | KMT2A 2491/4885RAB9A 3134/4885NPC1 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.